Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Abbott Laboratories    ABT   US0028241000

Delayed Quote. Delayed Nyse - 05/22 04:01:48 pm
49.03 USD   -0.63%
05/18DJCredits & Debits
05/14 ABBOTT LABORATO : Enters into Agreement with GE Healthcare
05/13 ASTRAZENECA : Enters Companion Diagnostic Test Deal With Abbott
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201220132014201520162017
Sales39 87421 84820 24720 73021 98023 324
Operating income (EBITDA)12 6164 9745 8625 2275 7306 199
Operating profit (EBIT)9 8334 0464 3143 9954 4774 806
Pre-Tax Profit (EBT)6 2632 521----
Net income5 9632 5762 2843 3243 1393 381
EPS ( $)3,721,621,492,112,122,33
Dividend per Share ( $)1,670,640,900,951,031,12
Yield3,41%1,31%1,84%1,94%2,10%2,29%
Announcement Date01/23/2013
12:47pm
01/22/2014
12:44pm
01/29/2015
12:45pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201220132014201520162017
Debt9 6743 0863 7821 2931 7811 290
Finance------
Operating income (EBITDA)12 6164 9745 8625 2275 7306 199
Leverage
(Debt/EBITDA)
0,77x0,62x0,65x0,25x0,31x0,21x
Capital Expenditure1 7951 1451 0771 1351 2221 258
Book Value Per Share (BVPS)17,0 $16,3 $14,3 $17,5 $18,7 $19,9 $
Cash Flow per Share5,85 $2,11 $2,41 $3,36 $3,21 $3,61 $
Announcement Date01/23/2013
12:47pm
01/22/2014
12:44pm
01/29/2015
12:45pm
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 72 994 M$ -
Entreprise Value (EV) 74 286 M$ 74 775 M$
Valuation 2015e 2016e
PER (Price / EPS) 23,3x 23,1x
Capitalization / Revenue 3,52x 3,32x
EV / Revenue 3,58x 3,40x
EV / EBITDA 14,2x 13,1x
Yield (DPS / Price) 1,94% 2,10%
Price to book (Price / BVPS) 2,81x 2,62x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) 19,3% 20,4%
operating Leverage (Delta EBIT / Delta Sales) - 2,00x
Net Margin (Net Profit / Revenue) 16,0% 14,3%
ROA (Net Profit / Asset) 7,23% 7,82%
ROE (Net Profit / Equities) 13,6% 13,9%
Rate of Dividend 45,2% 48,6%
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   5,47% 5,56%
Cash Flow / Sales (Taux d'autofinancement) 24,1% 21,7%
Capital Intensity (Assets / Sales) 2,22x 1,83x
Financial Leverage (Net Debt / EBITDA) 0,25x 0,31x
Price Earning Ratio
EPS & Dividend